Medincell shares break through €29.06, following the Uzedy sales published in early November
The Montpellier-based biopharmaceutical company continues its rebound in a Paris market that is slightly better oriented. The stock exceeds a several-week high, after very strong sales for its flagship treatment marketed by Teva.
Medincell shares gain 2.25% to €29.08 intraday, while the SBF 120 rises 0.37%. The stock has broken upward through its €29.06 resistance, the highest of the last 30 sessions, and is holding above it. This level now acts as support, with the next resistance at €29.56.
The price is well above its 20-day moving average (an 8% gap), extending a move underway for several weeks: +10.3% over seven days and +17% over one month. Over one year, the stock remains down 8%.
Uzedy sales and Teva's raised forecast
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The rebound is based on figures published in early November. Net sales of Uzedy, a schizophrenia treatment based on Medincell's technology, reached $85 million in the third quarter, up 96% year on year. These figures are Teva's, which markets the product in the United States and promptly raised its annual forecast to $290-310 million, from $270-290 million previously.
Medincell also obtained a €13.8 million non-dilutive loan in mid-October, which complements the debt restructuring launched in July. According to the consensus of the analysts surveyed, the stock trades at about 56.5 times next fiscal year's earnings.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T4 2025
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
